Updated:
Neuroflow
Neuroflow: Founded in 2016 by Christopher Molaro, the Philadelphia software company deploys behavioral health monitoring across hundreds of US health...
Neuroflow
Neuroflow was founded in Philadelphia in 2016 by Christopher Molaro, a former US Army officer, and Adam Pardes, an engineer with a background in medical devices. The company emerged from Molaro's experience observing fragmented behavioral health tracking in military settings. It now operates as a venture-backed software company selling into integrated health networks, the Department of Veterans Affairs, and commercial payers. Neuroflow sells a cloud-based platform that collects patient-reported outcomes, biometric data from wearables, and claims data to generate risk scores and clinical decision support for behavioral health. Deployment targets integrated care models — primary care, pain management, and dedicated behavioral health units. The software spans depression, anxiety, PTSD, and substance-use monitoring. Confirmed deployments include the Veterans Health Administration, Magellan Health, and Jefferson Health. Cigna Ventures joined the cap table in a 2021 round. The geographic footprint concentrates on the US, with VA contracts establishing a national presence. Neuroflow has disclosed roughly $55 million in total venture funding across rounds led by firms including Concord Health Partners, SEMCAP Health, and Cigna Ventures. The company has not publicly reported a headcount since its 2021 Series B, though job listings point to an engineering and clinical-sales hub in Philadelphia. No adjacent philanthropic or real-asset vehicles are disclosed. In October 2023, the company announced an expanded contract with the US Department of Veterans Affairs to scale its mental health monitoring software across additional VA medical centers (per VA public contracting records, October 2023). Neuroflow occupies a structural niche between health-tech SaaS and care delivery: it does not employ clinicians or bill for care, yet its software generates clinical risk scores that influence treatment decisions. This positions the company as a regulatory and reimbursement gatekeeper rather than a provider — a model that aligns its growth with payer-led mental-health parity enforcement, not fee-for-service volume.
General information
Firm type
Asset Manager
Year founded
2016
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Philadelphia
Corporate office
Philadelphia, PA, United States
Principals
Christopher Molaro
Co-Founder & CEO
Adam Pardes
Co-Founder & COO
Sector focus
Frequently asked questions
Who founded Neuroflow and what was the founding thesis?
Neuroflow was founded in 2016 by Christopher Molaro and Adam Pardes. Molaro served as a US Army officer before attending Wharton, where he observed that behavioral health lacked the remote monitoring tools standard in diabetes or cardiac care. The thesis was that payers and integrated health systems would eventually require objective, continuous mental-health data to manage risk — the same way labs and vitals drive decisions in physical medicine.
Does Neuroflow employ clinicians or directly deliver care?
No. Neuroflow is a software company, not a care provider. It does not employ therapists, psychiatrists, or social workers, and it does not bill for clinical services. Its platform aggregates patient-reported outcomes, device data, and claims signals into dashboards and risk scores that existing clinical teams use to triage and monitor behavioral health.
What government contracts does Neuroflow hold?
Neuroflow holds at least one known contract with the US Department of Veterans Affairs, the largest integrated behavioral health provider in the country. The VA began deploying Neuroflow's platform to monitor mental health risk across its network, and a 2023 contract expansion signaled broader roll-out across additional VA medical centers (per VA public contracting records, October 2023).
How is Neuroflow funded and who are its key investors?
Neuroflow has raised approximately $55 million in disclosed venture funding. Known backers include Concord Health Partners, SEMCAP Health, and Cigna Ventures — the venture arm of the health insurer Cigna — which participated in a 2021 funding round. The presence of a strategic payer investor signals alignment with insurer-driven behavioral health integration initiatives.
What is Neuroflow's revenue model and how does it sell?
Neuroflow sells enterprise software licenses to health systems, payers, and government agencies — primarily in the United States. The platform is typically priced on a per-member-per-month or per-seat SaaS model. Revenue scales with the number of covered lives under contract rather than fee-for-service clinical volume, aligning the company's growth with payer contracts, not patient visits.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: